Wells Fargo initiates Bio-Rad with an Equal Weight, $340 price target

As previously reported, Wells Fargo initiated coverage of Bio-Rad with an Equal Weight rating and $340 price target. While Bio-Rad appears undervalued on every metric, the firm believes management needs to address questions around CEO succession, plans for Sartorius, capital allocation and set new LRP growth/margin targets before the relative discount will contract.